# Quick Status: Adaptive Trial Capabilities

## Can the package simulate adaptive trials? **NO** ❌

### What's Missing (Critical)

1. **No Interim Analysis** (despite detailed plan existing)
   - Cannot do ANY early stopping
   - Cannot do group sequential designs
   - Required for 84% of adaptive trials

2. **No Binary Outcomes**
   - Cannot simulate response rates
   - Cannot do mortality endpoints
   - Required for most Phase II/III trials

3. **No Survival Outcomes**
   - Cannot do time-to-event
   - Cannot simulate oncology trials
   - Cannot do cardiovascular endpoints

## What Would Make It Minimally Viable?

**3 Essential Components** (estimated 7 weeks total):

### Component 1: Interim Analysis (3 weeks)
- Implement existing plan in `/dev/interim_analysis_implementation_plan.md`
- Enables group sequential designs
- Enables early stopping

### Component 2: Binary Outcomes (1 week)
```r
# Need to create:
build_model("binary_2arms")
# For response rates, mortality, success/failure
```

### Component 3: Sample Size Re-estimation (2 weeks)
- Conditional power
- Variance re-estimation
- Dynamic sample size

## Common Use Cases We CANNOT Handle

| Use Case | Why We Can't | What's Needed |
|----------|--------------|---------------|
| Stop early for futility | No interim analysis | Implement interim plan |
| Response rate endpoint | No binary outcomes | Add logistic model |
| Survival trial | No time-to-event | Add Cox model |
| Increase sample size | No SSR | Add re-estimation |
| Adaptive randomization | No RAR | Add allocation updates |
| Dose finding | No dose models | Add CRM/BOIN |
| Platform trial | No dynamic arms | Major refactor |

## Quick Comparison

| Feature | rctbayespower | rpact | gsDesign | EAST |
|---------|---------------|-------|----------|------|
| Group Sequential | ❌ | ✅ | ✅ | ✅ |
| Binary Outcomes | ❌ | ✅ | ✅ | ✅ |
| Survival Outcomes | ❌ | ✅ | ✅ | ✅ |
| Sample Size Re-est | ❌ | ✅ | ✅ | ✅ |
| Adaptive Random | ❌ | ✅ | ❌ | ✅ |
| Bayesian | ✅ | ❌ | ❌ | ✅ |
| ROPE | ✅ | ❌ | ❌ | ❌ |

## Bottom Line

**Current State:** Good for fixed sample Bayesian power (continuous only)
**For Adaptive Trials:** Not ready - missing ALL core adaptive features
**Time to MVP:** ~7 weeks of development
**Unique Value:** Bayesian + ROPE (if adaptive features added)